Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

After review of the interim analysis results, the independent Data Monitoring Committee (DMC)
recommended to stop the study based on positive efficacy findings for the primary efficacy
endpoint according to pre-specified stopping rules. Pfizer accepted the DMC recommendation
and made the decision to stop the study on September 7, 2011.

Inclusion Criteria:

- Diagnosis of epilepsy with partial seizures.

- Males or females, age 18 years or older.

- Documented history of at least 4 partial seizures in the 8 weeks prior to the
screening visit.

- Stable treatment with 1 to 2 anti-epileptic drugs in the 8 weeks prior to the
screening visit.

Exclusion Criteria:

- Current diagnosis of febrile seizures or seizures related to an ongoing acute medical
event.

- Seizures occurring only in cluster patterns, or seizures of a metabolic, toxic or
infectious origin.

- Primary generalized epilepsy or status epilepticus within the previous year.